BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9282426)

  • 1. New aromatase inhibitors for breast cancer.
    Drug Ther Bull; 1997 Jul; 35(7):55-6. PubMed ID: 9282426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Hamilton A; Piccart M
    Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
    Dranitsaris G; Leung P; Mather J; Oza A
    Anticancer Drugs; 2000 Aug; 11(7):591-601. PubMed ID: 11036964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
    Geisler J
    Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
    Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
    Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):859-63. PubMed ID: 16770112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Sainsbury R
    Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors in advanced breast cancer.
    Mouridsen HT
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation aromatase inhibitors--from the advanced to the adjuvant setting.
    Buzdar AU
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S13-7; discussion S33-5. PubMed ID: 12353818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.